Company Overview
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -36.5%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -36.47% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -76.12% |
| 6 Months: | -54.09% |
| 3 Months: | -55.19% |
| 1 Month: | -39.97% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)25.50 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -36.5% CAGR over 5 years.
- Trading 80.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BBLG Bone Biologics Corporation PHARMA | 0.56 | -2.00 | $1.54M | 0.00% | -60.16% | -54.96% | - | -36.47% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Apr 2014 | Jun 2014 | Jul 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07B | - | - | 1.07B | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04M | 748.08K | 715.27K | 733.11K | 805.05K |
| Operating Income | - | -316.49K | - | -1.73M | -923.42K | -510.58K | -2.97M | -9.10M | -4.34M | -3.86M | -2.16M | 1.97M | -1.13M | -1.10M | -860.15K | 404.79K | -1.19M | -679.26K | -301.31K | -340.05K | -132.71K | -145.82K | -180.92K | -231.88K | -229.79K | -689.50K | -469.30K | -1.22M | -3.15M | -3.04M | -2.08M | -903.54K | -809.66K | -951.02K | - | -1.04M | -748.08K | -715.27K | -733.11K | -805.05K |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.04M | -748.08K | -715.27K | -733.11K | -805.05K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.02M | -740.52K | -666.74K | -684.64K | -765.99K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.78K | -427.57K | -1.31K | -2.61M | -1.64M | -890.80K | -3.36M | -12.26M | -4.70M | -4.22M | -2.92M | 1.02M | -2.38M | -1.45M | -1.26M | -241.74K | -1.41M | -925.55K | -561.42K | -596.90K | -380.03K | -394.05K | -431.75K | -491.90K | -509.30K | -689.50K | -469.30K | -1.22M | -3.71M | -1.77M | -1.92M | -865.97K | -783.73K | -941.00K | - | -1.02M | -740.52K | -666.74K | -684.64K | -765.99K |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.13 | - | - | 0.25 | - | - | -0.29 | - | - | - | - | - | - | - | - | - | - | - | -1.36 | -3.53 | -55.20 | -5.21 | -4.90 | -1.31 | -4.02 | -14.21 | - | -1.92 | -1.33 | -0.37 | - | -0.43 |
| R&D Expense | - | 133.46K | - | 256.46K | 188.29K | 175.01K | 302.66K | 4.68M | 2.32M | 2.47M | 406.89K | 423.93K | 234.26K | 369.01K | 187.46K | -1.07M | 564.33K | 417.56K | 44.94K | 167.10K | 9.00K | 142.88K | 45.50K | 2.02K | - | 36.40K | 17.60K | 769.41K | 2.59M | 2.30M | 1.57M | 245.62K | 350.44K | 429.75K | - | 423.58K | 191.61K | 187.81K | - | 141.60K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2008 | Oct 2009 | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 1.07B | 1.07B | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.67M | 9.43M | 4.22M | 3.23M |
| Operating Income | - | - | - | - | - | - | -671.99K | -3.01M | -12.00M | -20.41M | -2.63M | -2.79M | -2.45M | -825.01K | - | -3.67M | -9.43M | -4.22M | -3.23M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.67M | -9.43M | -4.22M | -3.23M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 805.11K | 0 | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.48M | -8.95M | -4.11M | -3.11M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.60K | - | - | - | - |
| Net Income | -13.34K | -10.29K | -3.60K | -4.92K | -5.63K | -5.21K | -1.08M | -4.42M | -13.88M | -25.88M | -7.05M | -4.43M | -3.42M | -1.82M | - | -1.48M | -8.95M | -4.11M | -3.11M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -186.90 | -204.06 | -28.96 | -2.65 |
| R&D Expense | - | - | - | - | - | - | 188.24K | 623.52K | 3.67M | 10.17M | 1.42M | 104.49K | 1.10M | 340.67K | 82.04K | 1.58M | 6.91M | 2.13M | 1.06M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2007 | Oct 2008 | Oct 2009 | Oct 2010 | Oct 2011 | Oct 2012 | Dec 2012 | Oct 2013 | Dec 2013 | Dec 2014 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | 0 | 500 | - | 380 | 87.31K | 3.82M | 1.55M | 4.32M | 2.33M | 771.39K | 701.14K | 1.70M | 868.39K | 1.67M | 795.66K | 1.04M | 30.83K | 0 | - | 8.50M | 3.74M | 3.86M | 5.80M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.50M | 3.74M | 3.86M | 5.80M |
| Cash & Equivalents | - | - | - | - | 0 | 500 | 2.37K | 380 | 1.54K | 2.66M | 1.12M | 4.22M | 2.19M | 688.23K | 620.38K | 1.61M | 783.01K | 1.62M | 690.28K | 955.37K | 24.14K | - | - | 7.54M | 3.03M | 3.33M | 5.33M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 579.91K | 328.84K | 0 | 9.89K |
| Total Liabilities | - | - | - | 24.05K | 28.97K | 35.10K | - | 40.19K | 5.70M | 7.52M | 7.23M | 7.55M | 7.71M | 7.73M | 9.06M | 9.54M | 10.54M | 11.85M | 9.19M | 9.64M | 11.90M | 13.69M | - | 2.55M | 831.40K | 377.71K | 418.59K |
| Current Liabilities | - | - | - | - | - | - | - | - | 5.70M | 3.87M | 2.15M | 484.01K | 481.70K | 335.62K | 1.50M | 1.81M | 2.68M | 3.82M | 961.79K | 9.64M | 578.45K | 13.69M | - | 2.55M | 831.40K | 377.71K | 418.59K |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | -9.72K | -10.17K | -20.45K | -24.05K | -28.97K | -34.60K | -4.68M | -39.80K | -5.61M | -3.70M | -4.20M | -3.23M | -5.38M | -6.96M | -8.36M | -7.85M | -9.68M | -10.18M | -8.40M | -8.60M | -11.87M | -13.69M | - | 5.95M | 2.91M | 3.48M | 5.38M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.63K | 89.04K | 492.33K | 1.80M |
Cash Flows (Annual)
Figures in USD.
| Metric | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.68K | -3.60K | -6.06K | -6.12K | -525.37K | -2.76M | -3.55M | -7.33M | -3.33M | -4.10M | -3.25M | -426.93K | -1.23M | -3.57M | -9.56M | -4.12M | -2.69M |
| Investing Cash Flow | - | - | - | - | - | 25.48K | -504 | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | 5.68K | 3.60K | 6.56K | 6.00K | 524.53K | 5.39M | 2.00M | 6.83M | 3.40M | 4.37M | 2.32M | 402.79K | 7.90M | 4.43M | 5.04M | 4.42M | 4.70M |
| Capital Expenditure | - | - | - | - | - | -11.90K | -504 | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | -2.77M | -3.55M | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Oct 2008 | Oct 2009 | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | -0.2% | -0.1% | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | -0.3% | -0.2% | - | - | - | - | - |
| ROE % | 131.3% | 50.3% | 15.0% | 17.0% | 16.3% | 13.1% | 19.3% | 119.6% | 330.6% | 309.4% | 84.0% | 51.5% | 28.9% | 13.3% | - | -25.0% | -307.9% | -118.0% | -57.8% |
| ROCE % | - | - | - | - | - | - | 12.0% | 5,645.7% | 2,005.0% | 2,549.4% | 1,581.0% | 32.5% | 446.9% | 6.0% | - | -61.6% | -324.4% | -121.1% | -60.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 0.87% | 23.88K | $12.39K |
| 2 | Tower Research Capital LLC (TRC) | 0.07% | 1.95K | $1.01K |
| 3 | SBI Securities Co., Ltd. | 0.01% | 230 | $119 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BBLG
Six Australian hospitals agree to join Bone Biologics' bone-graft trial - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNRUFTRnlfT0dJaWRHNVk2RzFzdXdKM2kzSUtrN3J5RThIcXJVQTBCUHRJZXdETDFwWmZmcVl4X3NjMVZnQkZjQ1FJZWdlWF9nWUNwVFFhT1RFX2xhUjJHbUNiX2JKdW1LQkxubW44MU96Q3NhOU42WHRXTk9UNjRpZUJnTFpKck5UX1o0?o…
BBLG | Bone Biologics Corp Common Insider Trading - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE8tQUJfbzZGNzVWOXJvcWs0RGRZdkx4S2JLZm1hN0w4VjBQTHdFZXE0UWtsMk01TEgxYk80bkQyT1BCSGtXWFNVMzdmaU1DOExwWkY2WGVpMlNHZVRa?oc=5" target="_blank">BBLG | Bone Biologics Corp Common Insider T…
BBLG - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFA4WnJZUHNkUFozakR1TDc0VEFkTEhadE5sNDZEak1xQXRqMUZpUFZOWFF5bHRMdml0T19DdmdULVhzVlpaanc?oc=5" target="_blank">BBLG</a> <font color="#6f6f6f">Finviz</font>…
A company developing bone products will meet investors in New York - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNcTJ2dXA3YjREdGFNNXlZbUlIZkMyY2ZLa2ljZi1kTzRMa1RNRFFlQTZsM01Jamp0ZG9rVE4zcUVZdnZPOGRfRDlPUlphSWRlOTdBejRxS0pnd1N5cnZHTlRoMzZIZ2tibk1pTHJpR3V6QlpReEN3NUhvZ1ZYeXRKODAxSC1ZcGU4ekQ4UE…
Bone Biologics Extends rhNELL-1 Validated Shelf Life to 32 Months as NB1 Study Advances - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQMVNoZ2JKMi11NGxWeWpGS3ZQUUpTdFRxZ0M3MWxaSUtGenV6ejN6MGQ2SEtIZTkxM1RJNkpzM1RzUjR0eE5sM1pVd2R6ZG9xMlB4dm5XWnAzQ1hpZzhLYmJDM1NrQ255RVdZLUtDZ0t1VmRDMVIzcmlaVG1IUnVPeWVFZHF3MUdIUXVSSU…
Enterprise value to revenue forward of Bone Biologics Corp – NASDAQ:BBLG - tradingview.com
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPZTVMenJwQ1ZDNHBxUnB3YllRYUh6RzJQMjBmb3ZwQ3pJR3dKUlpSS2FsT2ZjX3lMT0RXdkdSbVdsVUwwODNGUjRVNHlMNTlVOWNBNEdzNzdYbjFIanVBSzBSYjdLWDZPeHoyajZqMjRzSG5uQk1nTWlKUFJuWDZDcFVDZFdCeFM4QmZpam…
BBLG — Frequently Asked Questions
What is the current share price of Bone Biologics Corporation (BBLG)?
As of 2026-09-19 21:16 PDT, Bone Biologics Corporation (BBLG) trades at $0.56 on NasdaqCM. Its 52-week range is $0.55 to $2.85.
What is the market capitalisation of BBLG?
Bone Biologics Corporation (BBLG) has a market capitalisation of $1.54M on NasdaqCM.
What is the P/E ratio of BBLG?
BBLG trades at a trailing price-to-earnings (P/E) ratio of -2.00. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.26.
What is the return on equity (ROE) of BBLG?
BBLG has a return on equity (ROE) of -54.96%. Its return on capital employed (ROCE) is -60.16%.
Is BBLG a good stock to buy?
This page provides a data-driven analysis of Bone Biologics Corporation (BBLG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.